Evidence map›Paper›PMID 42162871›Full record

ReviewEndocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists2026

Impact of Genetics on Endocrine Manifestations of Cystic Fibrosis.

Malinda Wu, Monica E Bianco, Scott M Blackman

Abstract readReview
In one paragraph

Review in Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Malinda WuDivision of Endocrinology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: mwu86@jhmi.edu.
Monica E BiancoDepartment of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Division of Pediatric Endocrinology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.
Scott M BlackmanDivision of Endocrinology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Funding

Developing a predictive risk score for pre-diabetes in youth.K23DK139457 · NIDDK · LURIE CHILDREN'S HOSPITAL OF CHICAGO · PI Monica Bianco · 2025 to 2026
$380k
Genetic Modifiers and Diagnostics for Bone Health in Cystic FibrosisK23AR084615 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI Malinda Wu · 2025 to 2026
$352k
NIAMS NIH HHS K23 AR084615NIDDK NIH HHS K23 DK139457
6 · The paper itself

Abstract

Cystic fibrosis (CF) is a monogenic multisystem disorder. Endocrine complications of CF are common and include diabetes, growth disorders, and bone disease among others. CF endocrinopathies may be influenced by 2 classes of genetic factors: (1) disease-causing cystic fibrosis transmembrane receptor (CFTR) variants that determine the level of CFTR dysfunction, and (2) variants in other genes throughout the genome known as genetic modifiers. This review highlights the impact of these genetic factors on selected endocrine manifestations of CF. CF-related diabetes (CFRD): CFRD is dependent on both variation at CFTR and genetic modifiers. Some genetic modifiers identified for CFRD influence non-CF forms of diabetes, eg, type 2 diabetes, highlighting overlapping pathophysiology, while others appear to be unique to CFRD. Other CFRD modifiers influence multiple CF manifestations, suggesting influence of the CF disease process itself. Growth disorders: Genetic investigations of growth and nutritional status have likewise identified both CFTR and non-CFTR genetic influences, with the latter revealing overlapping as well as distinct pathophysiological mechanisms involved in weight regulation in the general population. CF-related bone disease: Fewer CF-related bone disease studies have been conducted, but osteoporosis in the general population is a highly heritable trait with more than 1000 genetic modifiers already identified. Like studies of diabetes and growth, identifying genetic modifiers of osteoporosis-related traits in CF will likely reveal how pathophysiology of CF and non-CF bone disease is overlapping or distinct. Consideration of genetic influences on CF endocrinopathy can lead to better understanding for these endocrine manifestations in and outside of CF.

Indexed as

Cystic FibrosisEndocrine System DiseasesCystic Fibrosis Transmembrane Conductance RegulatorDiabetes MellitusHumansCFTR protein, humanCystic Fibrosis Transmembrane Conductance Regulator

Identifiers

PMID42162871
PMCPMC13358989

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.